Skip to main content

Table 3 Potential factors associated with HCC

From: Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study

High-risk vs. low-risk
  Univariate Multivariate
  p value OR 95% CI p value OR 95% CI
THRI 0.001 1.015 1.006–1.024 0.035 1.026 1.002–1.051
BMI 0.266 1.063 0.954–1.184 0.778 1.042 0.784–1.383
ALT 0.352 1.001 0.999–1.003 0.714 1.010 0.958–1.065
AST 0.420 1.001 0.998–1.004 0.089 1.045 0.993–1.099
GGT 0.198 0.998 0.994–1.001 0.293 0.994 0.982–1.005
ALB 0.878 1.004 0.956–1.054 0.394 1.097 0.886–1.359
TBil 0.930 1.000 0.991–1.008 0.328 0.960 0.885–1.042
Cr 0.376 0.996 0.987–1.005 0.775 0.990 0.927–1.058
AFP 0.021 1.022 1.003–1.041 0.770 1.004 0.979–1.028
APRI 0.182 1.040 0.982–1.102 0.294 0.540 0.170–1.710
FIB-4 0.099 1.035 0.993–1.079 0.793 1.045 0.753–1.451
MELD 0.794 0.993 0.938–1.050 0.713 0.920 0.589–1.436
Child-Pugh Score 0.714 1.035 0.863–1.241 0.068 4.269 0.896–20.330
Intermediate-risk vs. Low-risk
  Univariate Multivariate
  p value OR 95% CI p value OR 95% CI
THRI 0.101 1.010 0.998–1.023 0.692 1.012 0.954–1.074
BMI 0.696 1.033 0.877–1.217 0.881 1.041 0.612–1.773
ALT 0.505 0.996 0.986–1.007 0.679 0.972 0.848–1.113
AST 0.458 0.996 0.985–1.007 0.846 1.016 0.869–1.187
GGT 0.549 0.999 0.995–1.002 0.144 1.015 0.995–1.035
ALB 0.992 1.000 0.929–1.077 0.076 1.972 0.931–4.176
TBil 0.520 0.996 0.983–1.009 0.866 0.958 0.580–1.582
Cr 0.588 1.002 0.996–1.007 0.410 0.928 0.777–1.109
AFP 0.922 1.000 0.990–1.009 0.973 1.002 0.907–1.107
APRI 0.390 0.883 0.665–1.173 0.213 0.044 0.000–5.946
FIB-4 0.392 0.958 0.867–1.058 0.105 3.604 0.766–16.965
MELD 0.621 1.020 0.944–1.102 0.814 1.162 0.333–4.051
Child-Pugh Score 0.752 1.048 0.784–1.402 0.158 20.454 0.309–1355.822
  1. OR odds ratio, CI confidence interval, THRI Toronto hepatocellular carcinoma risk index, BMI body mass index, INR international normalized ratio, PT prothrombin time, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase, ALB albumin, TBil total bilirubin, Cr creatinine, AFP alpha fetoprotein, APRI AST to platelet ratio index, FIB-4 Fibrosis-4 score, MELD model for end-stage liver disease
  2. The italicized data were statistically significant